Thus, this study provided experimental evidence that FBXW7 ameliorated hepatic inflammation and insulin resistance by suppressing the expression and release of HMGB1 in NAFLD. This evidence concerns the gene HMGB1 and metabolic dysfunction-associated steatotic liver disease.